Signal
Rejoni Secures 25 Million Dollars to Commercialize Juveena Hydrogel for Uterine Healing
- Category
- · Funding · Global
- Date
- July 1, 2026
- Source
- OVUM
Summary
Clinical-stage medical device company Rejoni has raised $25 million in Series B extension funding to support the FDA approval process and commercial launch of its Juveena Hydrogel System, designed to prevent intrauterine adhesions following surgical procedures.
The company works in Devices and Therapeutics, and this round at Series B ($25M) is new money into that part of the market. Compare it with other recent rounds to see whether prices here are rising or holding steady.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.